About Zenotech Laboratories Limited
Data last updated:
Zenotech Laboratories Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Sun Pharmaceutical Industries Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 June 1989 and has been in existence for over 37 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L27100TG1989PLC010122. Its GSTIN is 36AAFCS6617R1ZM (Telangana). The company holds 4 GST registrations, of which 1 is active. Its shares are listed on BSE: 532039.
The company has an authorised share capital of ₹100 Cr and a paid-up capital of ₹61.03 Cr. It is led by directors including Azadar Husain Asghar Mehdi Khan and Jignesh Anantray Goradia.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹43.61 Cr, a growth of 1.3% compared to the previous year. For the same year it recorded a net loss of ₹1.11 Cr (net margin -2.5%) and EBITDA of ₹8.98 Cr (EBITDA margin 20.6%). The net worth stands at ₹95.12 Cr (down 1.1% YoY). Total assets are valued at ₹98.27 Cr (down 0.2% YoY).
The company has about 181 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Zenotech Laboratories. As per MCA filings, the company has open charges of ₹6 Cr and satisfied charges of ₹64.71 Cr on record. Court records list 36 cases involving the company, including 13 filed by the company and 23 filed against it; 5 cases are pending. The company has 11 deals on record (6 market trades, 3 acquisitions, 1 secondary share transfer); the latest was in March 2022. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 3 smaller; the largest is T. C. Health Care Private Limited with revenue of ₹45.32 Cr. The company has 3 MSME Form 1 returns on record between 2018 and 2020, listing 24 overdue payments to 18 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zenotechlab.com.
Company details
CIN history
Zenotech Laboratories has one previous CIN (Corporate Identification Number): L27100AP1989PLC010122. The current CIN is L27100TG1989PLC010122, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L27100TG1989PLC010122 | Current |
| L27100AP1989PLC010122 | Previous |
Contact details
Zenotech Laboratories Limited's registered office is in Hyderabad, Telangana. Its website is zenotechlab.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressSurvey No.250 – 252 Turkapally Village Genome Valley Road, Shamirpet Mandal Medchal – Malkajgiri District, Hyderabad, Telangana, India – 500101
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Zenotech Laboratories Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Zenotech Laboratories operates one associated brand: Zenotech Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generic injectables for oncology and anesthesiology are manufactured. | zenotechlab.com |
Business activity
The main business activity of Zenotech Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Zenotech Laboratories Limited, buy the company report.
Financials of Zenotech Laboratories Limited
FY 2025-26 filings availableZenotech Laboratories Limited reported revenue of ₹43.61 Cr (up 1.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 43.61 | 43.05 | 40.83 | 42.42 | 36.57 | 22.45 | 26.02 |
| Revenue growth | +1.3% | +5.4% | -3.8% | +16.0% | +62.9% | -13.7% | - |
| EBITDA | 8.98 | 14.18 | 17.22 | 20.71 | 17.46 | 6.39 | 8.99 |
| EBITDA margin | +20.6% | +32.9% | +42.2% | +48.8% | +47.7% | +28.5% | +34.6% |
| Profit before tax | 4.18 | 10.69 | 11.13 | 14.51 | 9.90 | (1.21) | 10.79 |
| Net profit | (1.11) | 2.88 | 8.32 | 11.56 | 22.17 | (1.21) | 4.42 |
| Net profit margin | -2.6% | +6.7% | +20.4% | +27.3% | +60.6% | -5.4% | +17.0% |
| EPS (₹) | (0.18) | 0.92 | 1.36 | 1.90 | 3.63 | (0.20) | 1.77 |
| Balance sheet | |||||||
| Total assets | 98.27 | 98.44 | 92.68 | 84.27 | 78.51 | 70.90 | 71.54 |
| Net worth | 95.12 | 96.13 | 90.54 | 82.27 | 70.64 | 48.41 | 49.63 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 20.66 | 21.42 |
| Cash & bank | 30.42 | 26.70 | 19.69 | 11.14 | 2.41 | 2.46 | 1.12 |
| Net working capital | 28.99 | 23.40 | 12.65 | (0.34) | (8.21) | (7.61) | (8.32) |
| Cash flow | |||||||
| Cash from operations | 10.20 | 9.54 | 11.82 | 20.66 | 17.67 | 5.74 | 11.38 |
| Cash from investing | (6.49) | 15.21 | (21.15) | (5.82) | (1.84) | (4.82) | (20.79) |
| Cash from financing | 0.00 | 0.00 | 0.00 | (6.11) | (15.87) | 0.45 | (2.70) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.62 | 9.89 | 12.86 | 11.23 | 9.64 | 12.13 | 11.24 | 9.77 |
| Revenue growth (YoY) | +10.2% | -18.5% | +14.4% | +14.9% | -2.7% | - | - | - |
| Other income | 0.44 | 0.65 | 0.42 | 0.75 | 0.59 | 0.49 | 1.00 | 1.69 |
| Total expenses | 9.75 | 9.71 | 8.89 | 8.95 | 7.18 | 7.71 | 7.37 | 7.36 |
| EBITDA | 0.87 | 0.18 | 3.97 | 2.28 | 2.46 | 4.42 | 3.87 | 2.41 |
| EBITDA margin | +9.1% | +2.0% | +33.6% | +22.3% | +28.5% | +39.8% | +37.9% | +27.5% |
| Depreciation | 1.90 | 1.76 | 1.80 | 1.78 | 1.77 | 1.73 | 1.76 | 1.75 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.59) | (0.93) | 2.59 | 1.25 | 1.28 | 3.18 | 3.11 | 2.35 |
| Tax | (0.15) | 2.21 | 0.66 | 2.09 | 0.29 | 1.95 | 1.42 | 1.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.62 | 9.89 | 12.86 | 11.23 | 9.64 | 12.13 | 11.24 | 9.77 |
| Revenue growth (YoY) | +10.2% | -18.5% | +14.4% | +14.9% | -2.7% | - | - | - |
| Other income | 0.44 | 0.65 | 0.42 | 0.75 | 0.59 | 0.49 | 1.00 | 1.69 |
| Total expenses | 9.75 | 9.71 | 8.89 | 8.95 | 7.18 | 7.71 | 7.37 | 7.36 |
| EBITDA | 0.87 | 0.18 | 3.97 | 2.28 | 2.46 | 4.42 | 3.87 | 2.41 |
| EBITDA margin | +9.1% | +2.0% | +33.6% | +22.3% | +28.5% | +39.8% | +37.9% | +27.5% |
| Depreciation | 1.90 | 1.76 | 1.80 | 1.78 | 1.77 | 1.73 | 1.76 | 1.75 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.59) | (0.93) | 2.59 | 1.25 | 1.28 | 3.18 | 3.11 | 2.35 |
| Tax | (0.15) | 2.21 | 0.66 | 2.09 | 0.29 | 1.95 | 1.42 | 1.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 43.61 | 43.05 | 40.83 | 42.42 | 36.57 | 22.45 | 26.02 |
| Revenue growth | +1.3% | +5.4% | -3.8% | +16.0% | +62.9% | -13.7% | - |
| Other income | 2.31 | 3.47 | 1.00 | 1.08 | 0.63 | 0.41 | 7.54 |
| Total expenses | 34.63 | 28.87 | 23.61 | 21.71 | 19.11 | 16.06 | 17.03 |
| Employee cost | 15.53 | 12.38 | 9.46 | 7.88 | 7.10 | 6.49 | 5.76 |
| EBITDA | 8.98 | 14.18 | 17.22 | 20.71 | 17.46 | 6.39 | 8.99 |
| EBITDA margin | +20.6% | +32.9% | +42.2% | +48.8% | +47.7% | +28.5% | +34.6% |
| Depreciation | 7.11 | 6.96 | 7.09 | 7.17 | 6.97 | 6.46 | 4.85 |
| Interest | 0.00 | 0.00 | 0.00 | 0.11 | 1.22 | 1.55 | 0.89 |
| Profit before tax | 4.18 | 10.69 | 11.13 | 14.51 | 9.90 | (1.21) | 10.79 |
| Tax | 5.26 | 5.08 | 2.84 | 2.92 | (12.27) | 0.00 | 0.00 |
| Net profit | (1.11) | 2.88 | 8.32 | 11.56 | 22.17 | (1.21) | 4.42 |
| Net profit margin | -2.6% | +6.7% | +20.4% | +27.3% | +60.6% | -5.4% | +17.0% |
| EPS (₹) | (0.18) | 0.92 | 1.36 | 1.90 | 3.63 | (0.20) | 1.77 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 |
| Reserves & surplus | 34.09 | 35.10 | 29.51 | 21.24 | 9.61 | (12.62) | (11.40) |
| Shareholders' funds (net worth) | 95.12 | 96.13 | 90.54 | 82.27 | 70.64 | 48.41 | 49.63 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 20.66 | 21.42 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 20.66 | 21.42 |
| Total liabilities | 98.27 | 98.44 | 92.68 | 84.27 | 78.51 | 70.90 | 71.54 |
| Assets | |||||||
| Gross block | 125 | 116 | 114 | 107 | 105 | 101 | 69.52 |
| Net block | 62.29 | 60.86 | 65.58 | 65.39 | 70.91 | 74.23 | 48.73 |
| Capital work in progress | 3.60 | 3.57 | 1.96 | 4.98 | 0.28 | 2.18 | 29.08 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.84 | 0.00 | 0.06 | 0.06 | 0.09 |
| Sundry debtors | 8.78 | 7.45 | 3.25 | 3.32 | 3.93 | 3.80 | 1.86 |
| Cash & bank balances | 30.42 | 26.70 | 19.69 | 11.14 | 2.41 | 2.46 | 1.12 |
| Loans & advances | 1.84 | 1.64 | 2.39 | 1.80 | 0.97 | 1.02 | 2.63 |
| Total current assets | 41.04 | 35.79 | 26.17 | 16.26 | 7.37 | 7.34 | 5.70 |
| Total current liabilities | 12.05 | 12.39 | 13.52 | 16.60 | 15.58 | 14.95 | 14.02 |
| Net working capital | 28.99 | 23.40 | 12.65 | (0.34) | (8.21) | (7.61) | (8.32) |
| Total assets | 98.27 | 98.44 | 92.68 | 84.27 | 78.51 | 70.90 | 71.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 26.58 | 1.82 | 11.14 | 2.41 | 2.46 | 1.08 | 13.20 |
| Net cash from operating activities | 10.20 | 9.54 | 11.82 | 20.66 | 17.67 | 5.74 | 11.38 |
| Net cash from investing activities | (6.49) | 15.21 | (21.15) | (5.82) | (1.84) | (4.82) | (20.79) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | (6.11) | (15.87) | 0.45 | (2.70) |
| Net change in cash | 3.71 | 24.76 | (9.33) | 8.73 | (0.04) | 1.38 | (12.11) |
| Closing cash | 30.42 | 26.70 | 19.69 | 11.14 | 2.41 | 2.46 | 1.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.3% | +5.4% | -3.8% | +16.0% | +62.9% | -13.7% | - |
| EBITDA growth | -36.7% | -17.7% | -16.9% | +18.6% | +173.2% | -28.9% | - |
| PBT growth | -60.9% | -4.0% | -23.3% | +46.6% | +9998.0% | - | +9998.0% |
| Net income growth | -138.5% | -65.4% | -28.0% | -47.9% | +1932.2% | -127.4% | - |
| Revenue CAGR (3Y) | +0.9% | +5.6% | +22.1% | +17.7% | +41.1% | +26.3% | +126.1% |
| EBITDA CAGR (3Y) | -24.3% | -6.7% | +39.2% | +32.1% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -2.5% | +13.0% | +20.3% | +27.3% | +60.6% | -5.4% | +41.5% |
| Return on capital employed | 0.0% | +3.2% | +4.1% | +5.3% | +6.4% | 0.0% | +3.0% |
| Return on net worth | 0.0% | +1.1% | +3.1% | +4.3% | +13.9% | 0.0% | +2.9% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.22 | 0.43 | 0.47 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.22 | 0.21 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.81 | 11.63 | -2,214.29 | 21.50 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.36 | 0.37 | 0.37 | 0.40 | 0.35 | 0.26 | 0.40 |
| Inventory turnover | 0.00 | 102.50 | 97.21 | 1,414.00 | 609.50 | 299.33 | 77.67 |
| Debtors turnover | 5.37 | 8.05 | 12.43 | 11.70 | 9.46 | 7.93 | 12.33 |
| EPS (₹) | (0.18) | 0.92 | 1.36 | 1.90 | 3.63 | (0.20) | 1.77 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 15.59 | 15.75 | 14.84 | 13.48 | 11.57 | 7.93 | 8.13 |
To see the full year-wise statements and ratios of Zenotech Laboratories Limited, buy the company report.
Board of directors of Zenotech Laboratories Limited
Zenotech Laboratories has 6 current directors and 37 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Azadar Husain Asghar Mehdi Khan | Director | 25 Aug 2015 | 11 Years 1 Months | Current |
| Jignesh Anantray Goradia | Director | 08 Jul 2015 | 11 Years 3 Months | Current |
| Jagruti Prashant Sheth Also directs: Monika Alcobev Limited | Director | 01 Feb 2020 | 6 Years 8 Months | Current |
| Rakeshchandra Jagdishprasad Sinha Also directs: Caraco Pharmaceuticals Private Limited, Sun Pharma Laboratories Limited, Neetnav Real Estate Private Limited and 5 more | Director | 01 Feb 2020 | 6 Years 8 Months | Current |
| Premal Hemant Gandhi Also directs: Dheevit Consultant Private Limited, Keshava Foundation for Educare | Director | 28 Jan 2025 | 1 Years 8 Months | Current |
| Nikkhil Venilal Kothhari Also directs: Fairpoint Estate LLP | Director | 23 Jan 2026 | 0 Years 8 Months | Current |
Peer comparison
Zenotech Laboratories Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| T. C. Health Care Private Limited | ₹45.32 Cr (FY 2025) | -40.0% | Modinagar, Uttar Pradesh, India | |||
| Saintlife Pharmaceuticals Limited | ₹45.01 Cr (FY 2025) | 26.0% | Dehradun, Uttarakhand, India | |||
| Rhombus Pharma Pvt Ltd | ₹44.95 Cr (FY 2024) | 1.0% | Gandhinagar, Gujarat, India | |||
| Deccan Remedies Ltd | ₹44.53 Cr (FY 2025) | 117.0% | Hyderabad, Telangana, India | |||
| Admed Pharma Private Limited | ₹44.5 Cr (FY 2025) | 17.0% | Delhi, India | |||
| Lincoln Parenteral Limited | ₹44.48 Cr (FY 2020) | -13.0% | Ahmedabad, Gujarat, India | |||
| Zenotech Laboratories Limitedthis company | ₹43.61 Cr (FY 2026) | -₹1.11 Cr | -2.5% | 1.3% | 181 | Hyderabad, Telangana, India |
To see the full peer comparison of Zenotech Laboratories Limited, buy the company report.
Auditor
Zenotech Laboratories Limited is audited by PKF Sridhar & Santhanam LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PKF Sridhar & Santhanam LLP | FY 2024 | 003990S/S200018 |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 68.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 1.00% and retail and other public shareholders hold 30.20%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 68.80% | 68.80% | 68.80% | 68.80% |
| Public | 31.20% | 31.20% | 31.20% | 31.20% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Oct 2005 | 90119394 | Technology Development Board | ₹6 Cr | Open | |
| 20 Mar 2012 | 10348257 | Hdfc Bank Limited | ₹15 Cr | Satisfied | |
| 17 Jan 2008 | 10085425 | Yes Bank Limited | ₹10 Cr | Satisfied | |
| 24 May 2006 | 10003366 | Indian Overseas Bank | ₹10 Cr | Satisfied | |
| 19 Jan 2006 | 80020977 | Andhra Bank | ₹4 Cr | Satisfied |
To see the full charge records of Zenotech Laboratories Limited, buy the company report.
Total charge records: 10 View all charges
Deals & funding
Zenotech Laboratories Limited has 11 deals on record (6 market trades, 3 acquisitions, 1 secondary share transfer); the latest was in March 2022.
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: Sun Pharmaceutical Industries Limited Seller: Daiichi Sankyo Company Limited |
| Apr 2014 | Acquisition | Undisclosed | Buyer: Sun Pharmaceutical Industries Limited |
| Jul 2009 | Market trade | ₹4.76 Cr | Buyer: Deutsche Trustee Services (India) Private Limited |
| Jan 2008 | Acquisition | ₹258.08 Cr | Buyer: Ranbaxy Laboratories Ltd |
| Nov 2007 | Market trade | ₹252.13 Cr | Buyer: Ranbaxy Laboratories Ltd Seller: an individual |
To see the full deal history of Zenotech Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Zenotech Laboratories Limited has 36 court cases on record: 13 filed by Zenotech Laboratories, 23 filed against it. 5 cases are pending and 31 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 29 | 20 | 4 |
| District courts | 7 | 3 | 1 |
Cases on record (5 of 36)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Writ petition | Filed by the company against The Branch Manager, Axis Bank Ltd. Begumpet, Hyderabad. and 7 others | Disposed |
| High Court, TELANGANA | Court case (CAPPEAL) | Filed against the company by Ranbaxy Laboratories Limited | Disposed |
| High Court for State of Telangana | Court case (COMPA) | Filed against the company by Ranbaxy Laboratories Ltd, | Disposed |
| High Court, TELANGANA | Court case (CAPPEAL) | Filed by the company against Ranbaxy Laboratories Limited, and 24 others | Disposed |
| High Court, TELANGANA | Arbitration matter | Filed against the company by Gannon Dunkerley & Co. Ltd | Disposed |
To see the full case history of Zenotech Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Zenotech Laboratories Limited has 3 MSME Form 1 returns on record between 2018 and 2020, listing 24 overdue payments to 18 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 18)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Simson Life Sciences Private Limited | |||
| Pci Analytics Private Limited | |||
| an individual supplier | |||
| KKB Micro Testing Labs Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Zenotech Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Zenotech Laboratories Limited has a workforce of 181 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
GST
Zenotech Laboratories has 4 GST registrations: 1 active and 3 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCS6617R1ZM | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Zenotech Laboratories Limited, buy the company report.
Recent activity
Zenotech Laboratories Limited has 71 board changes on record since 2003: 39 appointments and 32 cessations. The latest: Nikkhil Venilal Kothhari was appointed as Director on 23 Jan 2026.
84 earlier events are in the company report.
Frequently asked questions
Zenotech Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 June 1989 (37+ years old) and is registered under CIN L27100TG1989PLC010122. Listed on BSE: 532039.
Zenotech Laboratories reported revenue of ₹43.61 Cr for FY 2025-26 (up 1.3% YoY) based on standalone financials.
Zenotech Laboratories has 6 current directors:
- Azadar Husain Asghar Mehdi Khan - Director
- Jignesh Anantray Goradia - Director
- Jagruti Prashant Sheth - Director
- Rakeshchandra Jagdishprasad Sinha - Director
- Premal Hemant Gandhi - Director
- Nikkhil Venilal Kothhari - Director
The latest financial statements of Zenotech Laboratories on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Zenotech Laboratories is 36AAFCS6617R1ZM, registered in Telangana. The company has 4 GST registrations in all, of which 1 is active and 3 are cancelled or inactive.
The CIN (Corporate Identification Number) of Zenotech Laboratories is L27100TG1989PLC010122. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Zenotech Laboratories is listed on BSE with code 532039.
Zenotech Laboratories has 36 court cases on record: 13 filed by the company and 23 filed against it. 5 are pending. Most are in the high courts.
Zenotech Laboratories was incorporated on 15 June 1989, making it 37+ years old. It is registered with the Registrar of Companies, Hyderabad.
Zenotech Laboratories has 11 deals on record (6 market trades, 3 acquisitions, 1 secondary share transfer); the latest was in March 2022.
The peers of Zenotech Laboratories by revenue are T. C. Health Care Private Limited, Saintlife Pharmaceuticals Limited, Rhombus Pharma Pvt Ltd, Deccan Remedies Ltd, Admed Pharma Private Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Nikkhil Venilal Kothhari was appointed as Director on 23 Jan 2026. Kavita Rakesh Shah ceased to be Director on 31 Mar 2025. Premal Hemant Gandhi was appointed as Director on 28 Jan 2025. Zenotech Laboratories has 71 board changes on record in total.